Aarti Pharmalabs Limited has announced its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company reported a net profit of ₹7,130.66 lakhs on a standalone basis and ₹7,614.27 lakhs on a consolidated basis. The Board also approved significant management changes, including the appointment of Shri Rashesh C. Gogri as Managing Director, effective October 1, 2026. Additionally, an approved capacity addition for an intermediate block is planned with a capex of ₹149 Crores.
Aarti Pharmalabs Reports Q1 FY27 Financials and Key Appointments
Aarti Pharmalabs Limited disclosed its financial performance for the first quarter of the fiscal year 2027, ending June 30, 2026. The company presented both standalone and consolidated unaudited financial results, highlighting key financial metrics and significant organizational changes approved by the Board of Directors.
Financial Performance (Q1 FY27)
On a standalone basis, Aarti Pharmalabs reported total revenue from operations of ₹53,458.78 lakhs. The net profit for the quarter stood at ₹7,130.66 lakhs, with total comprehensive income at ₹7,312.80 lakhs. For the consolidated results, total revenue from operations reached ₹53,579.69 lakhs, and the net profit was ₹7,614.27 lakhs, with total comprehensive income at ₹7,776.16 lakhs.
Key Management and Board Changes
The Board of Directors, acting on the recommendations of the Nomination and Remuneration Committee, has approved significant changes in key leadership roles. Effective October 1, 2026, Shri Rashesh C. Gogri (DIN: 00066291) will transition from Non-Executive Director to Managing Director. Concurrently, Smt. Hetal Gogri Gala (DIN: 00005499) will move from Managing Director to Executive Director. These appointments are subject to shareholder approval at the upcoming Annual General Meeting.
Capacity Expansion and Capex Approval
The company has also approved a capacity addition for a Development of Intermediate Block. This expansion is estimated to require a capital expenditure (capex) of approximately ₹149 Crores. The financing for this project is planned through internal accruals and borrowings. The rationale behind this expansion is to serve intermediate and CDMO customers, aligning with the company’s strategic growth objectives.
Committee Reconstitutions
In addition to the financial and management updates, the Board has approved the reconstitution of its key committees. The Audit Committee, Corporate Social Responsibility (CSR) Committee, and the Stakeholders Relationship Committee have had their members and designations updated, effective October 1, 2026, for the Audit and CSR committees, and with immediate effect for the Stakeholders Relationship Committee. Notable changes include Shri Bhavesh Vora as Chairman of the Audit Committee and Smt. Hetal Gogri Gala as Chairperson of the CSR Committee.
Auditor’s Limited Review Report
The accompanying unaudited financial results have undergone a limited review by the independent auditors, Gokhale & Sathe. The auditors’ report, dated August 7, 2026, states that based on their review, nothing has come to their attention that causes them to believe the statements are not prepared in accordance with Indian Accounting Standards and do not contain any material misstatements. Attention has also been drawn to Note 4 of the Statement concerning the restatement of figures for the quarter ended June 30, 2025, due to fair value adjustments on a foreign exchange derivative contract.
Source: BSE
